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Abstract
Objectives:  To  quantify  the  effect  of  statins’  use  on  Prostate  Speciﬁc  Antigen  (PSA)  levels  in
patients referred  to  prostate  biopsy  and  to  determinate  if  the  exposure  to  statins  must  be
considered  to  improve  the  prostate  cancer  diagnostic  accuracy  of  PSA.
Methods:  We  selected  551  subjects  with  PSA  <10.0  ng/mL,  referred  to  ultrasound  guided  trans-
rectal prostate  biopsy  and  classiﬁed  as  cancer  or  non-cancer  patients  after  biopsy.  Information
regarding  statins’  use  was  obtained  from  clinical  records.  We  used  path  analysis  to  quantify  the
direct (reﬂects  the  inﬂuence  on  PSA  biology  and  metabolism)  indirect  (reﬂects  the  inﬂuence
on PSA  through  the  effect  on  the  risk  of  prostate  cancer)  and  total  effects  (net  result  of  direct
and indirect  effects)  of  statins’  use  on  PSA.  We  used  Receiver  Operating  Characteristic  curves
to assess  the  global  predictive  accuracy  of  models  including  PSA,  age,  body  mass  index,  5--
reductase  inhibitors,  aspirin  and  statins’  use  for  distinguishing  between  prostate  cancer  and
benign conditions.
Results:  We  observed  a  negative  total  effect  of  statins  on  PSA  levels  (users  vs.  non-users:
−0.633 ng/mL;  95%  CI:  −1.087;  −0.179),  which  corresponds  to  approximately  8.9%  lower  levels
among statins’  users,  mostly  due  to  the  direct  effect  (−0.588  ng/mL;  95%  CI:  −1.034,  −0.141)
rather than  that  by  the  indirect  effect  (−0.045  ng/mL;  95%  CI:  −0.152,  0.061).  There  were
no statistically  signiﬁcant  differences  between  the  area  under  the  curve  corresponding  to  the
models with  or  without  statins  (P  =  0.274).∗ Corresponding author.
E-mail address: ana.ferro@ispup.up.pt (A. Ferro).
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusion:  In  patients  referred  to  prostate  biopsy,  statins’  use  contributed  to  lower  Prostate
Speciﬁc  Antigen  levels,  but  the  clinical  impact  in  these  patients  is  low.
© 2015  Associac¸ão  Portuguesa  de  Urologia.  Published  by  Elsevier  España,  S.L.U.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Uso  de  estatinas  e  níveis  séricos  do  antigénio  especíﬁco  da  próstata
Resumo
Objetivos:  Quantiﬁcar  o  efeito  do  uso  de  estatinas  nos  níveis  do  antigénio  especíﬁco  da  próstata
(PSA) em  doentes  submetidos  a  biópsia  prostática.  Determinar  se  o  uso  de  a  estatinas  deve  ser
considerado  para  melhorar  a  validade  do  PSA  no  diagnóstico  de  cancro.
Métodos:  Selecionámos  551  doentes  com  PSA  <  10,0  ng/mL,  referidos  para  biópsia  prostática
e classiﬁcados  como  «cancro» e  «não-cancro» após  biópsia.  A  informac¸ão  relativa  ao  uso  de
estatinas  obteve-se  nos  registos  clínicos  dos  doentes.  Usámos  «path  analysis» para  quantiﬁcar
os efeitos  direto  (reﬂete  a  inﬂuência  na  biologia  e  metabolismo  do  PSA),  indireto  (reﬂete  a
inﬂuência  no  PSA  através  do  efeito  no  risco  de  cancro  da  próstata)  e  total  (soma  dos  efeitos
direto e  indireto)  do  uso  de  estatinas  nos  valores  de  PSA.  Usámos  curvas  ROC  para  avaliar  a
validade de  modelos  que  incluíam  os  valores  de  PSA,  idade,  índice  de  massa  corporal,  uso  de
inibidores  da  5--reductase,  uso  de  aspirina  e  estatinas  para  distinguir  entre  cancro  da  próstata
ou situac¸ões  benignas.
Resultados:  Observámos  um  efeito  total  negativo  das  estatinas  nos  níveis  de  PSA  (utilizadores
vs. não-utilizadores:  −0,633  ng/mL;  95%  CI:  −1,087;  −0,179),  correspondendo,  aproximada-
mente, a  níveis  8,9%  menores  com  estatinas,  devido  principalmente  ao  seu  efeito  direto
(−0,588 ng/mL;  95%  CI:  −1,034,  −0,141)  em  vez  do  efeito  indireto  (−0,045  ng/mL;  95%  CI:
−0,152, 0,061).  Não  houve  diferenc¸as  estatisticamente  signiﬁcativas  entre  as  áreas  sob  a  curva
dos modelos  com  e  sem  estatinas  (p  =  0,274).
Conclusão:  Nos  doentes  referidos  para  biópsia,  o  uso  de  estatinas  contribuiu  para  menores
valores de  PSA;  o  impacto  clínico  nestes  doentes  é  baixo.
© 2015  Associac¸ão  Portuguesa  de  Urologia.  Publicado  por  Elsevier  España,  S.L.U.  Este
é um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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he  use  of  statins  has  been  increasing  over  the  last
wo  decades1,2 due  to  the  deﬁnition  of  successively
ower  cut-offs  for  cholesterol  levels  associated  with  high
ardiovascular  risk,3 the  changes  in  the  spectrum  of
tatins’  indication  --  with  recommendations  for  its  use  in
oth  primary  and  secondary  prevention  of  cardiovascular
vents  --3 and  the  intense  marketing  policies  by  pharmaceu-
ical  companies.4,5 Currently,  statins  are  among  the  most
rescribed  drugs  within  countries  of  the  Organization  for
he  Economic  Co-operation  and  Development  (OECD),  with
n  estimated  average  daily  consumption  of  91  Deﬁned  Daily
oses  (DDDs)  per  1000  people.6
In  addition  to  the  lipid  lowering  properties  of  statins,
hese  drugs  have  shown  anti-inﬂammatory,  anti-invasive,
umor  growth  suppressing,  apoptotic  and  angiogenesis
nhibiting  properties,  potentially  decreasing  the  risk  of  sev-
ral  cancers,7 including  prostate  cancer.7--9 Statins  may  also
ontribute  to  a  reduction  in  total  Prostate  Speciﬁc  Antigen
PSA)  levels  due  to  their  action  on  benign  prostatic  tis-
ue,  and  on  the  metabolism  of  cholesterol  --  a  precursor
n  the  synthesis  of  PSA.9 Epidemiological  evidence  supports
t
H
g
m lower  risk  of  prostate  cancer  among  statins  users,  and
everal  observational  studies  have  shown  that  non-cancer
atients  under  treatment  with  statins,  especially  long  ther-
py  courses,  present  lower  levels  of  serum  PSA.10--12
The  impact  of  statins  on  serum  PSA  levels  may  lead  to  a
ecrease  in  prostate  cancer  detection  when  using  the  tradi-
ional  cut-offs  for  reference  to  biopsy,11,13 and  adjustment
f  the  PSA  threshold  may  be  needed  among  statins’  users,
o  maximize  sensitivity  and  speciﬁcity.14
Therefore,  we  aimed  to  quantify  the  effect  of  using
tatins  on  PSA  levels,  and  to  assess  the  potential  impact  of
he  exposure  to  these  drugs  in  the  diagnostic  accuracy  of
SA,  among  patients  referred  to  prostate  biopsy.
ethods
tudy  population  and  data  sources
etween  October  2009  and  November  2012,  we  consecu-
ively  recruited  patients,  at  the  Department  of  Urology  of
ospital  de  São  João,  Porto,  Portugal,  referred  to  ultrasound
uided  trans-rectal  prostate  biopsy  on  the  basis  of  abnor-
al  digital  rectal  examination  (DRE)  or  PSA  ≥2.5  ng/mL,  and
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Cancer
(Yes/No)
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(Years)
PSA
(ng/mL)
Aspirin
(Yes/No)
0.557 (0.114; 1.001)
–0.001 (–0.010; 0.009)
–0.007 (0.002; 0.013)
–0.005 (–0.050; 0.041 )
Figure  1  Directed  Acyclic  Graph  (DAG)  representing  estimates  of  direct  (solid  thick  line)  and  indirect  (solid  dashed  lines)
effects of  statins  on  total  Prostate  Speciﬁc  Antigen  (PSA)  levels,  calculated  by  path  analysis.  Direct  effect  (statins  →  PSA):  ˇ1 =
−0.588 (−1.034;  −0.141),  Indirect  effect  (statins  →  cancer  →  PSA):  ˇ2 ×  ˇ3 =  −0.045  (−0.152;  0.061),  Total  effect:
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uˇ1 +  (ˇ2 ×  ˇ3)  =  −0.633  (−1.034;  −0.179).  Note:  The  regression  c
using linear  (presented  in  italic)  or  logistic  (bold)  regression  mo
selected  those  with  PSA  <10  ng/mL.  Before  undergoing  pros-
tatic  biopsy,  weight  and  height  were  measured  and  a  fasting
blood  sample  was  collected  for  assessment  of  PSA  and  free
PSA.  None  of  the  patients  had  received  hormone  therapy,
radiotherapy  or  chemotherapy  previously.
The  results  of  the  prostatic  pathology  assessment  (cancer
versus  non-cancer)  were  deﬁned  by  biopsy  (12--14  biopsy
cores).  The  participants  with  non-malignant  disease  in  the
ﬁrst  biopsy,  but  having  a  prostate  cancer  diagnosed  within
six  months,  were  considered  as  cancer  patients.
Information  gathered  by  the  physicians  regarding  the
patients’  prostatic  volume,  previous  medical  conditions
and  currently  used  medication  was  obtained  from  clini-
cal  records  for  a  total  of  551  patients.  Data  analysis  was
restricted  to  this  group.
Currently  used  medications  were  classiﬁed  according  to
the  Anatomical  Therapeutic  Chemical  (ATC)  classiﬁcation
system,  from  the  1st  level  --  anatomical  main  group--to
5th  level  --  chemical  substance  name  --15 depending  on  the
information  available.  Statins’  use  was  deﬁned  as  the  cur-
rent  treatment  with  any  of  the  drugs  belonging  to  ATC
level  C10AA  (Hydroxy-methylglutaryl  Coenzyme-A  --  HMG
CoA  --  reductase  inhibitors)  including  simvastatin  (C10AA01),
lovastatin  (C10AA02),  pravastatin  (C10AA03),  ﬂuvastatin
(C10AA04),  atorvastatin  (C10AA05),  rosuvastatin  (C10AA07)
or  pitavastatin  (C10AA08).  Data  on  speciﬁc  dosage,  duration
of  treatment  or  previously  discontinued  prescription  medi-
cations  were  not  systematically  recorded  and,  therefore,
not  considered  for  analysis.Statistical  analysis
To  compare  quantitative  and  categorical  variables  across
groups,  we  used  the  Mann--Whitney  and  the  Chi-square  tests,
l
O
d
bcients  (ˇ)  and  95%  conﬁdence  intervals  (95%  CI)  were  obtained
,  as  appropriate.
espectively.  Statistically  signiﬁcance  was  considered  when
 <  0.05.  All  reported  P-values  are  two-sided.
We  used  path  analysis  to  quantify  the  direct  (correspond-
ng  to  the  inﬂuence  on  PSA  biology  and  metabolism),  indirect
through  the  relation  with  the  risk  of  prostate  cancer,  which,
n  turn,  is  related  to  PSA  levels)  and  total  effect  (the  net
esult  of  direct  and  indirect  effects)  of  statins’  use  on  PSA
evels.16 This  method  is  an  extension  of  regression  analysis
hat  allows  for  simultaneous  estimation  of  the  interrelations
etween  variables  in  a  set,  as  well  as  to  decompose  the
agnitudes  of  effects  between  variables  with  complex  inter-
elations  --  which  represent  an  advantage  of  this  particular
ethod  --,  as  well  as  to  compare  them,  allowing  to  test  the
lausibility  of  mediation  effects.16
We  assumed  a  causal/temporal  relationship  between  the
se  of  statins  and  the  PSA  levels,  taking  into  account  several
otential  confounders,  as  depicted  in  the  Directed  Acyclic
raph  (DAG)17 presented  as  Fig.  1. The  model  reﬂects  the
inimum  set  of  variables  needed  to  estimate  the  global
ffect  of  statins  on  PSA  levels,  including  the  direct,  indirect
nd  total  effect.
Models  were  ﬁtted  with  Mplus  software  (Muthen´  and
uthen´,  Los  Angeles,  California);  95%  conﬁdence  inter-
als  were  calculated  by  bootstrapping,  and  the  models
ere  considered  to  have  a  good  ﬁt  when  the  estimated
oot  Mean  Square  Error  of  Approximation  (RMSEA)  was
0.05.18
We  ﬁtted  logistic  regression  models,  including  cancer  as
he  dependent  variable  and  different  combinations  of  PSA,
ge,  BMI,  5-  reductase  inhibitors  (5ARI),  aspirin  and  statins’
se  as  independent  variables,  due  to  their  impact  on  PSA
evels,  and  used  the  areas  under  the  corresponding  Receiver
perating  Characteristic  (ROC)  curves  to  compare  their  pre-
ictive  accuracy  to  distinguish  between  prostate  cancer  and
enign  prostatic  conditions.19 The  analyses  were  performed
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sing  STATA®, version  11.2  (StataCorp  LP,  College  Station,
X,  USA).
thical  consideration
he  project  was  approved  by  the  Hospital  de  São  João  Ethics
ommittee.
esults
here  were  a  total  of  138  statins’  users:  42.3%  used  simvas-
atin,  1.3%  lovastatin,  18.1%  pravastatin,  4.7%  ﬂuvastatin,
7.4%  atorvastatin,  12.8%  rosuvastatin  and  0.7%  pitavas-
atin.  Statins  users  were  signiﬁcantly  older  than  non-users
nd  presented  tendency  for  lower  tPSA  and  free/total  PSA
atio.  No  further  statistically  signiﬁcant  differences  were
bserved  according  to  the  use  of  statins,  except  for  lower
evels  of  free  PSA  in  statins’  users  among  cancer  patients
Table  1).
Fig.  1  presents  the  relation  between  the  variables  tested
o  assess  the  plausibility  of  an  effect  of  statins’  use  on
SA  levels,  using  path  analysis;  the  overall  ﬁt  of  the  model
as  good  (RMSEA  =  0.00).  We  observed  a  signiﬁcant  negative
otal  effect  of  statins  on  PSA  levels  (users  vs.  non-users:
0.633  ng/mL;  95%  CI:  −1.087;  −0.179),  which  corre-
ponds  to  approximately  8.9%  lower  levels  among  statins’
sers,  mostly  due  to  the  direct  effect  (users  vs.  non-users:
0.588  ng/mL;  95%  CI:  −1.034,  −0.141)  rather  than  that  by
he  indirect  effect  (users  vs.  non-users:  −0.045  ng/mL;  95%
I:  −0.152,  0.061).
Fig.  2  depicts  the  ROC  curves  that  reﬂect  the  global  pre-
ictive  accuracy  of  models  including  PSA,  age,  BMI,  5ARI,
spirin  and  statins’  use  for  distinguishing  between  prostate
ancer  and  prostate  benign  conditions.  There  were  no  sta-
istically  signiﬁcant  differences  between  the  area  under  the
urve  (AUC)  corresponding  to  the  models  with  or  without
tatins  (P  =  0.274).  Furthermore,  there  was  no  meaningful  or
tatistically  signiﬁcant  difference  in  the  predicted  probabil-
ty  of  prostate  cancer  detection  among  statins  users  (24%;
5%  CI:  17--31)  and  non-users  (27%;  95%  CI:  21--32)  when
etting  the  PSA  value  to  4 ng/mL  and  considering  the  mean
alues  of  the  remaining  variables  included  in  the  model.
When  restricting  the  analysis  to  cancer  patients,  taking
nto  account  the  use  of  statins  did  not  modify  the  predictive
ccuracy  of  PSA  to  distinguish  between  low  and  high-grade
isease  at  prostate  biopsy;  there  were  no  signiﬁcant  differ-
nces  between  the  AUC  obtained  from  the  models  presented
n  Fig.  3  (P  =  0.202).
iscussion
n  a  group  of  patients  referred  to  prostate  biopsy  there  was
 negative  effect  of  statins  on  PSA  levels.  According  to  the
odel  proposed  for  the  relation  between  statins  use  and  PSA
evels,  there  was  a  weak  association  when  considering  only
he  effects  mediated  by  the  potential  relation  between  the
se  of  statins  and  the  occurrence  of  cancer.Despite  the  overall  signiﬁcant  association  between
tatins  and  PSA,  no  important  difference  in  the  predictive
alue  of  PSA  testing  is  to  be  expected  according  to  the  use
f  these  drugs.
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Figure  2  Receiver  operating  characteristic  (ROC)  curves  for  global  predictive  accuracy  of  different  combinations  of  total  PSA
tors  (
r(PSA), age,  body  mass  index  (BMI),  aspirin,  5-  reductase  inhibi
under the  curve;  95%  CI,  95%  conﬁdence  interval.
Previous  studies  that  evaluated  the  relationship  between
statins  and  PSA  levels  found  lower  levels  of  PSA  among
statins  users10--13,20--22;  the  relative  difference  in  PSA  lev-
els  between  statins  users  and  non-users  was  −3%  and
−13%  after  one  and  ﬁve  years  of  therapy  with  statins,
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Figure  3  Receiver  operating  characteristic  (ROC)  curves  for  glob
(PSA), age,  body  mass  index  (BMI),  aspirin,  5-  reductase  inhibito
high-grade prostate  cancer  (Gleason  score  3  +  4  or  lower  vs.  4  +  3  o
interval.5ARI)  and  statins’  use  for  prostate  cancer  diagnosis.  AUC,  area
espectively,  in  a  sample  from  participants  in  the  National
ealth  and  Nutrition  Examination  Survey  (NHANES).13,20
owever,  methodological  differences  preclude  direct  com-
arison  between  our  results  and  the  ones  from  most  studies
onducted  before.
cificity
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Concerning  the  relationship  between  statins  and  can-
er,  we  observed  a  non-signiﬁcantly  lower  risk  of  prostate
ancer,  which  is  also  in  agreement  with  other  studies  that
sed  a  similar  setting--men  referred  to  prostate  biopsy.
n  these  studies,  the  risk  ratios  (RR)  for  prostate  cancer
iagnosis  were  0.92  (95%  CI:  0.85--0.99)23 and  0.95  (95%
I:  0.73--1.24)24 when  adjusting  for  different  confounders.
egarding  the  other  relations  depicted,  the  magnitudes  of
ffects  are  in  accordance  with  the  available  evidence  with
n  exception  for  the  association  between  aspirin  use  and
SA  levels,25,26 since  previous  observational  studies  showed
ower  PSA  levels  among  aspirin  users.13
Our  study  adds  to  previous  research  on  this  topic
 comprehensive  assessment  of  the  impact  of  use  of
tatins  in  prostate  cancer;  we  quantiﬁed  the  statins  direct
statins  →  PSA)  and  indirect  (statins  →  cancer  →  PSA)  effect
-  through  path  analysis  --  and  assessed  the  impact  of
ecreased  PSA  levels  among  statins’  users  in  the  prediction
f  prostate  cancer  --  through  ROC  curve  analysis.  Neverthe-
ess,  some  limitations  need  to  be  discussed.  The  absence  of
nformation  from  the  patient’s  clinical  records  regarding  the
uration  of  treatment  with  statins,  since  it  is  one  of  the  main
eterminants  for  statins  anti-carcinogenic  activity,10,13 con-
ributes  to  an  underestimation  of  the  association  between
tatins  and  prostate  cancer  and  may  help  to  explain  why
e  observed  a  larger  contribution  from  the  direct  effect  on
SA  levels.  The  cross-sectional  nature  of  our  analyses  does
ot  allow  us  to  conﬁrm  the  precedence  of  the  exposure  to
tatins  over  the  observed  PSA  levels.  Although  it  is  unlikely
hat  there  is  a  causal  relation  between  low  PSA  and  the  use
f  statins,  the  absence  of  information  regarding  access  to
ealth  care  services  could  have  resulted  in  an  overestima-
ion  of  the  direct  effects  of  statins  on  PSA  levels.12,26 People
ho  have  a  better  access  to  health  care  are  more  likely  to
e  prescribed  a  statin,  possibly  leading  to  lower  PSA  levels,
s  well  as  to  undergo  PSA  testing  more  frequently  and  to
e  diagnosed  with  a  prostate  cancer  on  the  basis  of  lower
SA  values.  This  probably  had  little  impact  in  the  internal
alidity  of  our  ﬁndings,  since  all  participants  were  referred
or  prostatic  biopsy  and  a  relatively  high  homogeneity  in
he  access  to  health  care  may  be  expected  among  them.
owever,  our  results  cannot  be  extrapolated  to  the  general
opulation  or  clinical  settings  with  different  risk  of  prostate
ancer.
In  conclusion,  in  a  consecutive  sample  of  patients
eferred  to  prostate  biopsy,  we  observed  that  statins’
se  was  associated  with  lower  PSA  levels,  but  the  clin-
cal  impact  of  this  relation  is  low.  Further  investigation
s  needed  to  obtain  more  robust  and  generalizable  esti-
ates  of  the  relation  between  the  use  of  statins  and  PSA
evels.
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